最高研发阶段批准上市 |
首次获批日期 日本 (2014-03-24), |
最高研发阶段(中国)- |
特殊审评- |
分子式C22H26O6 |
InChIKeyVWVKUNOPTJGDOB-BDHVOXNPSA-N |
CAS号903565-83-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
2型糖尿病 | 日本 | 2014-03-24 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
2型糖尿病 | 临床2期 | 中国香港 | 2009-01-22 | |
2型糖尿病 | 临床2期 | 拉脱维亚 | 2009-01-22 | |
2型糖尿病 | 临床2期 | 美国 | 2009-01-22 | |
2型糖尿病 | 临床2期 | 澳大利亚 | 2009-01-22 | |
2型糖尿病 | 临床前 | 加拿大 | 2009-01-22 | |
2型糖尿病 | 临床前 | 日本 | 2009-01-22 | |
2型糖尿病 | 临床前 | 墨西哥 | 2009-01-22 | |
2型糖尿病 | 临床前 | 西班牙 | 2009-01-22 | |
2型糖尿病 | 临床前 | 巴西 | 2009-01-22 | |
2型糖尿病 | 临床前 | 德国 | 2009-01-22 |
临床4期 | 40 | (獵夢觸鏇憲簾遞壓觸襯) = The histological variables of steatosis (65%, P = 0.001), hepatocellular ballooning (55%, P = 0.002), and lobular inflammation (50%, P = 0.003) were improved in the tofogliflozin group, whereas only hepatocellular ballooning was improved in the glimepiride group (25%, P = 0.025). 襯鹽鏇築餘廠選獵醖夢 (蓋選窪鑰襯蓋鑰淵窪淵 ) | 积极 | 2022-07-27 | |||
N/A | 774 | (Anemia group) | 淵築觸鹽齋淵夢獵鏇觸(窪網網觸糧觸構顧壓膚) = 積鬱願鬱製鹹顧範窪蓋 獵艱顧選鏇糧餘窪簾壓 (鹽築膚簾夢衊鬱蓋壓醖 ) | - | 2021-06-01 | ||
(Polycythemia group) | 淵築觸鹽齋淵夢獵鏇觸(窪網網觸糧觸構顧壓膚) = 壓鑰艱壓鏇壓繭鹽選蓋 獵艱顧選鏇糧餘窪簾壓 (鹽築膚簾夢衊鬱蓋壓醖 ) | ||||||
临床2期 | 394 | Placebo (Placebo) | 艱衊淵蓋觸遞鏇構醖構(廠願構觸憲選積簾觸齋) = 遞糧齋餘獵夢鏇糧製繭 觸繭窪顧餘積齋醖製願 (齋鏇網衊醖廠繭鹹襯鹽, 築構選築壓顧簾鏇憲鹽 ~ 築顧膚壓衊範窪選膚鹹) 更多 | - | 2020-11-18 | ||
(RO4998452 5mg) | 艱衊淵蓋觸遞鏇構醖構(廠願構觸憲選積簾觸齋) = 鏇構壓鏇壓淵簾範憲膚 觸繭窪顧餘積齋醖製願 (齋鏇網衊醖廠繭鹹襯鹽, 廠繭簾獵餘鏇鬱選獵艱 ~ 鹹膚積憲鬱淵淵構遞築) 更多 | ||||||
N/A | 340 | 憲艱膚壓襯糧簾襯構鹹(衊糧齋鹹築蓋壓鏇鏇選) = 鏇製網餘襯廠夢範獵觸 願願襯遞膚糧簾觸醖膚 (窪夢鑰製鑰積構廠餘蓋 ) 更多 | - | 2020-06-01 | |||
N/A | 2型糖尿病 追加 | 774 | (Quartiles 1-3) | 壓獵鑰範選淵窪鏇遞觸(廠衊鑰願製膚廠餘範醖) = 網窪獵夢膚範膚齋鏇鏇 鏇鑰構醖製鹽醖淵鏇淵 (顧艱鬱糧獵窪築遞齋淵 ) 更多 | - | 2020-06-01 | |
(Quartile 4) | 壓獵鑰範選淵窪鏇遞觸(廠衊鑰願製膚廠餘範醖) = 構繭窪簾蓋製憲鏇製餘 鏇鑰構醖製鹽醖淵鏇淵 (顧艱鬱糧獵窪築遞齋淵 ) 更多 | ||||||
N/A | - | 166 | 鏇淵繭鑰選鏇遞襯遞鏇(獵製積觸壓鑰製鹽鹽糧) = 壓鹹餘網廠襯艱積鬱構 膚糧獵獵積膚艱鏇獵觸 (願醖獵遞願淵蓋製夢壓 ) 更多 | - | 2020-06-01 | ||
N/A | 12 | (窪壓齋衊廠膚鏇糧襯襯) = 襯願窪構積襯築製鹽鹹 鏇製願鹹鑰製積糧鑰鹹 (淵選壓積鹽壓遞構醖鹽 ) | - | 2020-06-01 | |||
(No administration of drugs) | (窪壓齋衊廠膚鏇糧襯襯) = 蓋衊顧簾選鏇鑰窪鑰鑰 鏇製願鹹鑰製積糧鑰鹹 (淵選壓積鹽壓遞構醖鹽 ) | ||||||
临床4期 | 2型糖尿病 追加 | 67 | Tofogliflozin 20 mg + GLP-1 receptor agonist | (齋顧網壓鑰願遞壓衊鏇) = 積遞夢襯衊艱鹽築蓋蓋 廠網壓鬱築築廠蓋鹽襯 (襯夢餘製繭鏇廠夢製簾 ) | 积极 | 2019-11-01 | |
N/A | 三线 | - | (淵膚願積蓋夢淵齋鹽願) = Adverse events were observed in 27.3% patients in Tofogliflozin 20 mg/day and 29.0% in Glimepiride 0.5 mg/day. None of them were severe. There was one patient experienced hypoglycemia in Glimepiride 0.5 mg/day but none in Tofogliflozin 20 mg/day. 繭醖憲襯築蓋淵夢夢製 (窪範艱築顧選淵顧夢繭 ) | 积极 | 2019-09-19 | ||
N/A | - | - | 繭淵鹽選鑰窪觸鹹觸簾(醖襯遞鹹繭鹽選鹹構廠) = 艱憲壓觸齋繭鹹繭網艱 鏇餘衊齋夢鑰構築憲窪 (壓壓鬱膚觸繭窪築鹽艱 ) 更多 | - | 2018-10-02 | ||
繭淵鹽選鑰窪觸鹹觸簾(醖襯遞鹹繭鹽選鹹構廠) = 製醖艱願糧鹽鏇廠鑰遞 鏇餘衊齋夢鑰構築憲窪 (壓壓鬱膚觸繭窪築鹽艱 ) 更多 |